Clik here to view.
Kamada Receives FDA Approval For Emphysema Study
Israeli pharmaceutical company Kamada has announced that it has received FDA approval for a phase II and III clinical trial of AATD-IH, an inhalable version of its AAT drug, which is designed to treat...
View ArticleClik here to view.
Pharmaceutical Company Kamada Discovers Diabetes Drug Efficient For Lung Disease
Israeli drug company Kamada reports that on recent clinical trials done with its Glassia drug, results have shown positive results for treating lung disease. Laboratory mice with bacterial lung...
View ArticleClik here to view.
Kamada Report Successful Trial On Type 1 Diabetes Treatment
Israeli pharmaceutical company Kamada has announced positive results of its Phase I/II clinical trial of the company’s AAT protein, the active ingredient in its drug Glassia. The results indicate that...
View ArticleClik here to view.
Report: Kamada Plans To Raise $50M On Wall Street
Israeli pharmaceutical company Kamada Ltd., which specializes in developing, producing and marketing of specialty life-saving therapeutics, plans to raise some $50 million in stock. Business news...
View ArticleClik here to view.
Kamada Plans $69M Nasdaq IPO
Israeli pharmaceutical company Kamada Ltd., which is publicly traded on the Tel Aviv Stock Exchange, is planning to raise $69 million on Nasdaq. The funds will be raised in accordance to the companies...
View ArticleClik here to view.
Pharmaceutical Company Kamada Raises $51.6M On Nasdaq IPO
Israeli company Kamada, which develops treatments for orphan diseases, has raised less than it aimed for on its Nasdaq IPO. The company was hoping to raise up to $69 million, but was only able to raise...
View ArticleClik here to view.
Kamada Receives Orphan Drug Status For Glassia Treatment
October 30, 2014 | Kamada has been awarded orphan drug status from the US Food & Drug Administration for Glassia, a drug to treat Graft-versus-host-disease (GVHD). When a company receives orphan...
View Article‘Kamada’ Obtains FDA Approval For Cystic Fibrosis Drug Trial
Israeli bio-pharmaceutical company Kamada announced that it has obtained FDA approval to conduct a clinical trial in the US for the company’s next generation drug for the treatment of cystic fibrosis....
View Article‘Kamada’ Obtains FDA Approval For Cystic Fibrosis Drug Trial
Israeli bio-pharmaceutical company Kamada announced that it has obtained FDA approval to conduct a clinical trial in the US for the company’s next generation drug for the treatment of cystic fibrosis....
View ArticleIsraeli Biopharma Company Kamada To Roll Out Antibody Treatment For COVID-19
Israeli biopharmaceutical company Kamada announced that it completed development on a plasma-derived antibody treatment for COVID-19, also known as a passive vaccine. The Rehovot-based company plans...
View ArticleClik here to view.
Small Trial For COVID-19 Antibody Drug Gets Flying Start In Jerusalem
This article was first published by The Times of Israel and is re-posted with permission. The world’s first clinical trial for a coronavirus drug made from antibodies got off to a promising start in...
View ArticleClik here to view.
Early Results For COVID-19 Trial With Antibody Drug Show 90% Improvement Rate
Israeli biopharmaceutical company Kamada announced this week that interim initial results for a clinical trial involving its plasma-derived antibody treatment for COVID-19 show an improvement rate of...
View ArticleClik here to view.
Kamada Signs Deal To Supply Israel’s Health Ministry With COVID-19 Antibody Drug
Israeli biopharmaceutical company Kamada, the developer of plasma-derived antibody treatment for COVID-19 currently under trial, has signed a supply agreement with Israel’s Health Ministry for the...
View Article‘Kamada’ Obtains FDA Approval For Cystic Fibrosis Drug Trial
Israeli bio-pharmaceutical company Kamada announced that it has obtained FDA approval to conduct a clinical trial in the US for the company’s next generation drug for the treatment of cystic fibrosis....
View Article